Hilda A Mujuru
Overview
Explore the profile of Hilda A Mujuru including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
325
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
White E, Kityo C, Spyer M, Mujuru H, Nankya I, Kekitiinwa A, et al.
Lancet HIV
. 2025 Feb;
12(3):e201-e213.
PMID: 39978387
Background: ODYSSEY showed superior efficacy for dolutegravir-based antiretroviral therapy (ART) versus standard of care (SOC) in children living with HIV starting first-line or second-line ART aged 4 weeks or older....
2.
Cunningham C, McFarland E, Muresan P, Capparelli E, Perlowski C, Johnston B, et al.
J Pediatric Infect Dis Soc
. 2025 Jan;
14(2).
PMID: 39821046
Background: Vertical HIV-1 transmission despite antiretroviral therapy may be mitigated by the use of long-acting, broadly neutralizing, monoclonal antibodies (bNAb) such as VRC07-523LS. The present study was designed to determine...
3.
Burnett E, Umana J, Anwari P, Mujuru H, Groome M, Van Trang N, et al.
J Infect Dis
. 2024 Nov;
PMID: 39607893
Background: Rotavirus vaccines are moderately protective against illness in high mortality settings compared with low mortality settings. Vaccine effectiveness (VE) evaluations may clarify our understanding of these disparities, but estimates...
4.
Oyenuga V, Mosler G, Addo-Yobo E, Adeyeye O, Arhin B, Fortune F, et al.
Lancet Child Adolesc Health
. 2024 Oct;
8(12):859-871.
PMID: 39447587
Background: Rapid urbanisation and population growth in sub-Saharan Africa has increased the incidence of asthma in children and adolescents. One major barrier to achieving good asthma control in these adolescents...
5.
Dzavakwa N, Kranzer K, Khan P, Mackworth-Young C, Mujuru H, Ferrand R, et al.
Int J Nurs Stud
. 2024 Sep;
160:104903.
PMID: 39303643
Objective: To systematically review literature from randomised controlled trials (RCTs) investigating the effectiveness of electronic monitoring device informed interventions on adherence and clinical outcomes in children and adolescents with chronic...
6.
Jacobs T, Waalewijn H, Houlden L, Bollen P, Nanduudu A, Nambi E, et al.
Br J Clin Pharmacol
. 2024 Sep;
90(11):2947-2952.
PMID: 39228168
Dolutegravir (DTG) is primarily metabolized by uridine diphosphate glucuronosyltransferases, forming the pharmacologically inactive DTG glucuronide (DTG-gluc). We described the dolutegravir metabolic ratio (DTG-MR; DTG-gluc AUC divided by DTG AUC) in...
7.
Ward V, Lee A, Hawken S, Otieno N, Mujuru H, Chimhini G, et al.
Clin Perinatol
. 2024 May;
51(2):301-311.
PMID: 38705642
Preterm birth (PTB) is the leading cause of morbidity and mortality in children globally, yet its prevalence has been difficult to accurately estimate due to unreliable methods of gestational age...
8.
Hui A, Chimhini G, Saungweme M, Kaisi D, Munetsi E, Mujuru H, et al.
BMC Pediatr
. 2024 Mar;
24(1):187.
PMID: 38493088
Background: Preterm birth (birth before 37 completed weeks of pregnancy) is the leading cause of neonatal and child under-five mortality globally, both of which are highest regionally in sub-Saharan Africa....
9.
Calderwood C, Marambire E, Nzvere F, Larsson L, Chingono R, Kavenga F, et al.
PLOS Glob Public Health
. 2024 Jan;
4(1):e0002630.
PMID: 38261562
The burden of non-communicable diseases (NCDs) in southern Africa is expanding and is superimposed on high HIV prevalence. Healthcare workers are a scarce resource; yet are vital to health systems....
10.
Jacobs T, Mumbiro V, Cassia U, Zimba K, Nalwanga D, Ballesteros A, et al.
Clin Infect Dis
. 2023 Oct;
78(3):702-710.
PMID: 37882611
Background: We evaluated dolutegravir pharmacokinetics in infants with human immunodeficiency virus (HIV) receiving dolutegravir twice daily (BID) with rifampicin-based tuberculosis (TB) treatment compared with once daily (OD) without rifampicin. Methods:...